Quality Control Scientist

Bachem confirms growth and expects a strong second half 2026. Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX - Group sales grew to CHF 326.4 million (+4.3% compared to the prior-year period, +7.3% in local currencies). - EBITDA amounted to CHF 82.8 million (-9.0% compared to the prior-year period, -4.2% in local currencies) with a margin of 25.4% (prior-year period: 29.1%). - Ramp-up costs for Building K affected the operating result as expected. - Bachem appoints Boris Corpataux as Chief Commercial Officer to the Corporate Executive Committee. Outlook. - For 2026, Bachem expects sales growth between 35% and 40% in local currencies. - Bachem confirms its outlook for an EBITDA margin in 2026 in local currencies in the low thirties. - The company plans to make investments between CHF 350 million and CHF 400 million in 2026. Group results. The Bachem Group (SIX: BANB) achieved sales of CHF 326.4 million in the first half of 2026 (+4.3% compared to the prior-year period: CHF 313.0 million). In local currencies (LC), sales increased by 7.3%. Operating income before depreciation and amortization (EBITDA) amounted to CHF 82.8 million (-9.0%, -4.2% in LC), and operating income (EBIT) was CHF 54.1 million (-19.1%, -13.1% in LC). As a result, the EBITDA margin was 25.4% (first half of 2025: 29.1%) and the EBIT margin was 16.6% (first half of 2025: 21.4%). In local currencies, the EBITDA margin was 25.9% and the EBIT margin was 17.3%. Net income increased to CHF 50.3 million (+0.3%) with a margin of 15.4% (first half of 2025: 16.0%) despite the expected ramp-up costs. In the clinical drug development category (CMC Development), sales increased to CHF 167.5 million (first half of 2025: CHF 123.7 million, +35.4%, in LC: +39.5%). The Commercial API category achieved sales of CHF 133.0 million (first half of 2025: CHF 168.4 million, -21.0%, in LC: -19.3%). The research chemicals and specialties business (Research & Specialties) delivered CHF 25.9 million (first half of 2025: CHF 20.8 million, +24.4%, in LC: +30.5%). Substantial capacity expansion. Bachem continued to pursue its comprehensive investment program to expand production capacity in the first half of 2026. A total of CHF 148.4 million was invested with significant volumes to be invested in the second half of the year. In addition to expansion, Bachem is also continuously optimizing the utilization of existing buildings and facilities through operational improvements. Building K, constructed for large-scale production, was successfully put into operation in 2026. Commercial GMP products are already being manufactured here. The facility is being gradually expanded to provide additional capacity. The successful ramp-up of commercial production is a key component of Bachem's long-term growth strategy. Bachem is planning for a large-volume manufacturing site in Sisslerfeld (Eiken, Switzerland). The first expansion phase of this project will be realized through a strategic collaboration, with an investment volume of more than CHF 500 million. Production at the new site is expected to start by 2030. Bachem continues to invest in its entire network of sites, focusing on site-specific core competencies. Also in the US, high-volume capacity is being expanded. At the same time, Bachem is also focusing on promising small-volume clinical projects in the US, while investments in Western Switzerland are aimed at securing the supply of key precursors. Bachem appoints Boris Corpataux to the Corporate Executive Committee. Bachem has appointed Boris Corpataux as Chief Commercial Officer effective August 1, 2026. In this role, he will become a member of the Corporate Executive Committee. Boris Corpataux brings extensive experience in sales and in working with strategic partners. He has been with the company for more than twenty years and has a deep understanding of Bachem's markets, business relationships, and long-term partnerships. With his appointment, Bachem ensures continuity in customer relationships and in its market-related priorities. For 2026, Bachem expects sales growth in local currencies between 35% and 40%. The EBITDA margin in local currencies should be in the low thirties. The company plans to invest between CHF 350 million and CHF 400 million in 2026. The Half-Year Report 2026 and the presentation for the analyst- and media call are available on the website under the following link: https://www.bachem.com/about-bachem/investor-hub/reports-and-presentations/ Financial calendar. * November 26, 2026 Capital Markets Day * March 4, 2027 Publication of Annual Report 2026 * April 28, 2027 Annual General Meeting (financial year 2026) * July 29, 2027 Publication of Half-Year Report 2027 About Bachem. Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial applications to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and production sites in Europe and the US. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com. | Media Patrick Barth Head Group Communications Tel.: +41 58 595 4522 Email: [email protected] | Investors Barbora Blaha Head Investor Relations Tel.: +41 58 595 0573 Email: [email protected] | This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.

Bachem stock holds gains as peptide demand supports revenue growth. Published on 07/22/2026 at 03:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Bachem stock reflects sustained demand for peptide and oligonucleotide APIs, with recent annual figures showing double digit revenue growth and an expanding order backlog. Bachem stock is tied closely to the performance of Bachem Holding AG (ISIN CH0012530207), a Swiss specialist in peptide and oligonucleotide active pharmaceutical ingredients for the global biotech and pharmaceutical industry. As a pure play on complex APIs, Bachem's share price tends to react to shifts in revenue growth, margins, and capacity expansion rather than short term macro headlines. In the most recent reported full year, Bachem generated around CHF 500 million in revenue, pointing to a business that has scaled meaningfully from the lower hundreds of millions a few years ago. For investors, the key signal is that peptide demand in areas like oncology and metabolic disease continues to underpin the companys order book and utilization rates. Revenue up double digits. Revenue is a central metric for assessing Bachem stock because the company operates in a niche but fast growing segment of the pharmaceutical supply chain. In its latest full year, Bachem reported revenues of roughly CHF 500 million, compared with about CHF 400 million in the prior year period, implying growth of around 25%. This step up in revenue, on a base that had already grown in previous years, indicates that the company is capturing a larger share of peptide and oligonucleotide outsourcing trends as more biopharmaceutical companies move complex synthesis to specialized suppliers. Beyond the headline revenue number, Bachem also reports operating profitability metrics that help frame the resilience of its business model. With EBITDA margin estimated in the mid to high twenties percent range, Bachem converts a substantial portion of its top line into operating cash flow that can be used for capacity expansion, process automation, and selective investments in new technologies. The combination of approximately CHF 500 million in sales and an EBITDA margin above 25% implies EBITDA on the order of CHF 125 million or more in the latest year, enough to fund expansion projects without overreliance on external capital. Order backlog and capacity expansion. For Bachem stock, another important fundamental metric is the order backlog, which reflects commitments from pharmaceutical and biotech clients over several years. Recent figures from the company context point to a backlog of several hundred million Swiss francs, providing multi year visibility into revenue and supporting decisions to invest in new manufacturing sites and equipment. When an order backlog expands faster than current year revenue, as has been the case for Bachem in recent reporting cycles, it signals that future sales could outpace historical levels once new capacity is fully online. Capacity expansion is critical because peptide and oligonucleotide synthesis is capital intensive and requires significant investment in reactors, purification systems, and quality control infrastructure. Bachem has been investing hundreds of millions of Swiss francs over several years into new facilities in Switzerland, Europe, and North America to meet demand from both large pharmaceutical companies and emerging biotech firms. These capital expenditures, while weighing on free cash flow in the short term, are designed to support revenue growth above CHF 500 million in coming periods and to maintain or improve the companys EBITDA margin once volume ramps at new sites. Read deeper More on Bachem fundamentals. Investors who want to explore the full set of financials, guidance, and strategic updates for Bachem can turn to the companys investor relations materials, which provide detailed tables and commentary on revenue, profitability, capital expenditure, and pipeline projects. Peptide APIs drive growth. On the product side, Bachem is best known for its portfolio of peptide APIs, which are used by pharmaceutical companies in therapies ranging from cancer treatments to metabolic and endocrine disorders. Peptides are short chains of amino acids that can be tailored to interact with specific targets in the body, and their complexity makes high quality manufacturing a specialized task. Bachem has built expertise over decades in solid phase and liquid phase peptide synthesis, purification, and analytical characterization, enabling it to serve both commercial scale products and clinical trial supplies. The company also has an expanding presence in oligonucleotide APIs, which are short strands of nucleic acids used in antisense and RNA based therapies. This segment complements its peptide business and positions Bachem to participate in a broader range of innovative modalities being developed in the biotech sector. As more RNA and DNA targeted drugs progress through clinical trials and into commercialization, demand for oligonucleotide APIs is likely to provide an additional layer of growth on top of peptide revenues. For Bachem, the combined opportunity in peptides and oligonucleotides supports the case for sustained capital investment and could help diversify revenue beyond any single therapeutic area. Stock valuation and market metrics. In equity market terms, Bachem stock is listed on the SIX Swiss Exchange, where it trades in Swiss francs and is followed by both domestic and international investors interested in life sciences suppliers. At a share price level in the low to mid triple digit CHF range, the implied market capitalization for Bachem stands in the low to mid single digit billions of Swiss francs, reflecting expectations for continued growth and profitability. Price to earnings and enterprise value to EBITDA multiples for the stock have at times traded above the broader market, thanks to the companys positioning in structurally growing end markets and its track record of revenue expansion from roughly CHF 400 million to about CHF 500 million over a year. Volatility in Bachem stock often comes from changes in guidance or updates on large scale capacity projects, rather than from short term macroeconomic swings. When the company confirms that demand is strong enough to support full utilization of new manufacturing lines, investors tend to look beyond near term capital expenditure peaks and focus on normalized profitability and cash generation. Conversely, if projects are delayed or customers adjust their ordering patterns, the stock can react as earnings trajectories are recalibrated. For long term holders, the key consideration is whether peptide and oligonucleotide outsourcing remains on an upward path and whether Bachem maintains its technological and quality advantages. Representative product line. Among its many offerings, Bachem markets a range of catalog peptides and custom manufactured APIs that support both research and commercial use. These products include amino acid derivatives, peptide fragments, and fully formulated active ingredients tailored to individual client specifications. The catalog segment provides recurring revenue from laboratories and smaller-scale users, while large custom projects for branded medicines can generate substantial multi year revenue streams. By balancing standardized catalog products with bespoke manufacturing, Bachem can smooth revenue and margin volatility while remaining closely tied to innovation in biotechnology. Share price context. For investors monitoring Bachem stock, the current share price on the SIX Swiss Exchange in Swiss francs sits in a range that implies a market capitalization in the low to mid single digit billions of CHF. This valuation embeds expectations that revenue, which has climbed from approximately CHF 400 million to about CHF 500 million in the most recent full year, will continue to grow as peptide and oligonucleotide demand stays firm. While day to day price moves can be influenced by sentiment and sector flows, the fundamental drivers remain capacity utilization, order backlog development, and margin resilience as new manufacturing sites ramp. Bachem stock facts. * Company: Bachem Holding AG * ISIN: CH0012530207 * Ticker: SIX: BACN * Trading venue: SIX Swiss Exchange * Market capitalization: Low to mid single digit billions CHF (recent period) * Sector / Industry: Health Care / Pharmaceuticals and Biotechnology suppliers * Index membership: Swiss mid cap and sector related indices Follow Bachem stock. Sponsored Ad Bachem stock: new analysis - 23 july. Fresh Bachem information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI. en | CH0012530207 | BACHEM | boerse | 69828914 | bgmi

Bachem to build large-scale production facility in Switzerland. The next phase of expansion for the Greenfield project in Sisslerfeld (Eiken, Switzerland) will be carried out as part of a strategic partnership. The investment totals more than 500 million CHF. Bachem announced the signing of an agreement for the supply of large quantities of peptides. As part of this agreement, Bachem will invest more than 500 million CHF in the greenfield project in Sisslerfeld. The strategic partnership includes upfront payments toward the investment costs and long-term commitments. Production at the new Sisslerfeld site is scheduled to begin in 2030. The partners have agreed not to disclose any further details. "Demand for peptides as active pharmaceutical ingredients remains high. Long-term supply agreements are crucial to guaranteeing security of supply for our customers and their patients. At the same time, they enable targeted capacity expansion," says Anne-Kathrin Stoller, CEO of Bachem. She adds: "This agreement strengthens Bachem's planning certainty beyond the year 2030. It allows us to responsibly coordinate investments across our entire production network, including Sisslerfeld." Bachem is currently implementing a program to expand production capacity across its entire network. This includes facilities for the large-scale production of peptides and oligonucleotides. In doing so, the company is strengthening its position as a leading global partner for TIDES. Bachem operates a global network of production sites, including Bubendorf (Switzerland), Sisslerfeld (Switzerland), Vionnaz (Switzerland), Vista (U.S.), Torrance (U.S.), and St. Helens (U.K.). Company. Hauptstr. 144 4416 Bubendorf Switzerland